Quality of life assessment in patients receiving adjuvant therapy for breast cancer: The IBCSG approach

Annals of Oncology

Volumn 8, Issue 9, 1997, Pages 825-835

  Bernhard, J ^a   Hurny C ^b   Coates, A S ^c   Peterson, H F ^d   Castiglione Gertsch, M ^a   Gelber, R D ^d   Goldhirsch, A ^e,f   Senn, H J ^g   Rudenstam, C M ^h  

^a IBCSG Coordinating Center   (Switzerland)

^b Medical Division Lory   (Switzerland)

^c UNIVERSITY OF SYDNEY   (Australia)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^f Ospedale Civico Lugano   (Switzerland)

^g CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^h SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Adjuvant therapy; Breast cancer; Cross cultural issues; Linear analogue self assessment (LASA) scales; Quality of life; Randomized controlled trials

Indexed keywords

ARTICLE; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CULTURAL FACTOR; HUMAN; MENOPAUSE; MOOD; PRIORITY JOURNAL; QUALITY OF LIFE; SOCIAL SUPPORT;

EID: 0030827706     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008269715091     Document Type: Article

References (45)

1. Goldhirsch A, Gelber RD, Simes RJ et al. for the Ludwig Breast Cancer Study Group. Costs and benefits of adjuvant therapy in breast cancer: A quality-adjusted survival analysis. J Clin Oncol 1989; 7: 36-44.
2. Hürny C, Bernhard J, Coates AS et al. Impact of adjuvant therapy on quality of life in women with node-positive operable breast cancer. International Breast Cancer Study Group. Lancet 1996; 347: 1279-84.
3. Hürny C, Bernhard J, Gelber RD et al. Quality of life measures for patients receiving adjuvant therapy for breast cancer: An international trial. The International Breast Cancer Study Group. Eur J Cancer 1992; 28: 118-24.
4. Coates A, Fisher Dillenbeck CF, McNeil DR et al. On the receiving end II. Linear analogue self-assessment (LASA) in evaluation of aspects of the quality of life of cancer patients receiving chemotherapy. Eur J Cancer Clin Oncol 1983; 19: 1633-7.
5. Coates A, Glasziou P, McNeil D. On the receiving end - III. Measurement of quality of life during cancer chemotherapy. Ann Oncol 1990; 1: 213-7.
6. Hürny C, Bernhard J, Bacchi M et al. The Perceived Adjustment to Chronic Illness Scale (PACIS): A global indicator of coping for operable breast cancer patients in clinical trials. Swiss Group for Clinical Cancer Research (SAKK) and the International Breast Cancer Study Group (IBCSG). Support Care Cancer 1993; 1: 200-8.
7. Zerssen D v. Clinical self-rating scales (CSRS) of the Munich Psychiatric Information System (PSYCHIS München). In Sartorius N, Ban TA (eds): Assessment of Depression. Berlin: Springer-Verlag 1986; 270-303.
8. Coates A, Abraham S, Kaye SB et al. On the receiving end - patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol 1983; 19: 203-8.
9. Hürny C, Bernhard J, Coates A et al. The quality of quality-of-life measurements. JAMA 1995; 273: 843.
10. Bernhard J, Hürny C, Coates A, Gelber RD. Applying quality of life principles in international cancer clinical trials. In Spilker B (ed): Quality of Life and Pharmacoeconomics in Clinical Trials. Philadelphia: Lippincott-Raven 1996; 693-705.
11. Hunt SM, Wiklund I. Cross-cultural variation in the weighting of health statements: A comparison of English and Swedish valuations. Health Policy 1987; 8: 227-35.
12. McCormack HM, de L. Horne DJ, Sheather S. Clinical applications of visual analogue scales: A critical review. Psych Med 1988; 18: 1007-19.
13. Priestman T, Baum M. Evaluation of quality of life in patients receiving treatment for advanced breast cancer. Lancet 1976; i: 899-900.
14. Baum M, Priestman T, West RR, Jones EM. A comparison of subjective responses in a trial comparing endocrine with cytotoxic treatment in advanced carcinoma of the breast. Euro J Cancer 1980; 16 (Suppl): 223-6.
15. Coates A, Gebski V, Bishop JF et al. for the Australian-New Zealand Breast Cancer trials Group. Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies. N Engl J Med 1987; 317: 1490-5.
16. Tannock IF, Boyd NF, DeBoer G et al. A randomized trial of two dose levels of cyclophosphamide, methotrexate and fluorouracil chemotherapy for patients with metastatic breast cancer. J Clin Oncol 1988; 6: 1377-87.
17. Fraser SC, Dobbs HJ, Ebbs SR et al. Combination or mild single agent chemotherapy for advanced breast cancer? CMF vs. epirubicin measuring quality of life. Br J Cancer 1993; 67: 402-6.
18. Sutherland HJ, Lockwood GA, Cunningham AJ. A simple, rapid method for assessing psychological distress in cancer patients: Evidence of validity for linear analog scales. J Psychosoc Oncol 1989; 7: 31-43.
19. Butow P, Coates A, Dunn S et al. On the receiving end IV: Validation of quality of life indicators. Ann Oncol 1991; 2: 597-603.
20. Kelsen DP, Portenoy RK, Thaler HT et al. Pain and depression in patients with newly diagnosed pancreas cancer. J Clin Oncol 1995; 13: 748-55.
21. Coates A, Gebski V, Signorini D et al. for the Australian New Zealand Breast Cancer trials Group. Prognostic value of quality-of-life scores during chemotherapy for advanced breast cancer. J Clin Oncol 1992; 10: 1833-8.
22. Coates A, Thomson D, McLeod GR et al. Prognostic value of quality of life scores in a trial of chemotherapy with or without interferon in patients with metastatic malignant melanoma. Eur J Cancer 1993; 29A: 1731-4.
23. Schipper H, Clinch J, McMurray A, Levitt M. Measuring the quality of life of cancer patients: The Functional Living Index-Cancer: Development and validation. J Clin Oncol 1984; 2: 472-83.
24. Dunn SM, Patterson PU, Butow PN et al. Cancer by another name: A randomized trial of the effects of euphemism and uncertainty in communicating with cancer patients. J Clin Oncol 1993; 11: 989-96.
25. Zigmund AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatrica Scandinavia 1983; 67: 362-70.
26. McNair DM, Lorr M, Droppleman LF. EITS manual for the profile of mood states. San Diego: Educational and Industrial Testing Service 1971.
27. Hürny C, Bernhard J, Coates AS et al. Responsiveness of a single-item indicator versus a multi-item scale: Assessment of emotional wellbeing in an international breast cancer trial. Med Care 1996; 34: 234-48.
28. Bernhard J, Peterson HF, Coates AS et al. for the International Breast Cancer Study Group (IBCSG). Quality of life assessment in international breast cancer study group (IBCSG) trials: Practical issues and factors associated with missing data. Stats Med 1997 (forthcoming).
29. Hürny C, Bernhard J, Coates A et al. for the International Breast Cancer Study Group. Timing of baseline quality of life assessment in an international adjuvant breast cancer trial: Its effect on patient self-estimation. Ann Oncol 1994; 5: 65-74.
30. Bernhard J, Hürny C, Coates AS et al. for the International Breast Cancer Study Group. Factors affecting baseline quality of life in two international adjuvant breast cancer trials. Submitted 1997.
31. Tchekmedyian NS, Cella DF, Winn RJ (eds). Economic and quality of life outcomes in oncology. A new focus for healthcare providers, payers, and policy makers. Proceedings of the fourth international quality of life symposium, Long Beach, California, 1995. Oncology 1995; 9 (Suppl): 211.
32. Tamburini M. Quality of life assessment in medicine. Milano: Glamm Interactive Srl 1996 (CD ROM).
33. Hürny C. Coping and survival in early breast cancer: An update. Recent Results Cancer Res 1993; 127: 211-20.
34. Maunsell E, Brisson J, Deschenes L. Social support and survival among women with breast cancer. Cancer 1995; 76: 631-7.
35. Hürny C, Wegberg BV, Bacchi M et al. Time trade-off (TTO) interviews vs. subjective health estimations (SHE) in metastatic breast cancer patients. Development and validation of a self-rated linear analogue scale. Submitted 1997.
36. Levine MN, Guyatt GH, Gent M et al. Quality of life in stage II breast cancer: An instrument for clinical trials. J Clin Oncol 1988; 6: 1798-810.
37. Sprangers MA, Groenvold M, Arraras JI et al. The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: First results from a three-country field study. J Clin Oncol 1996; 14: 2756-68.
38. Brady MJ, Cella DF, Mo F et al. Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument. J Clin Oncol 1997; 15: 974-86.
39. de Haes J, van Knippenberg F, Neijt J. Measuring psychological and physical distress in cancer patients: Structure and application of the Rotterdam Symptom Checklist. Br J Cancer 1990; 62: 1034-8.
40. Schag C, Ganz P, Heinrich R. Cancer Rehabilitation Evaluation System-Short Form (CARES-SF): A cancer specific rehabilitation and quality of life instrument. Cancer 1991; 68: 1406-13.
41. Aaronson NK, Ahmedzai S, Bergman B et al. The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365-76.
42. Cella DF, Tulsky DS, Gray G et al. The functional assessment of cancer therapy scale: Development and validation of the general measure. J Clin Oncol 1993; 11: 570-9.
43. Krause NM, Jay GM. What do global self-rated health items measure? Med Care 1994; 32: 930-42.
44. McHorney CA, Ware JE, Rogers WH et al. The validity and relative precision of MOS Short- and Long-Form Health Status Scales and Dartmouth COOP charts: Results from the medical outcomes study. Med Care 1992; 30 (Suppl): MS253-MS265.
45. Coates A, Porzsolt F, Osoba D for the Internationale Gruppe Lebensqualität in der Onkologie (IGLOO). Quality of life in oncology practice: Prognostic value of EORTC QLQ-C30 scores in patients with advanced malignancy. Eur J Cancer (in press).